[Therapeutic future of trimethoprim-sulfamethoxazole in toxoplasmosis].
D000818:Animals; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D051379:Mice; D011247:Pregnancy; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use*; D014123:Toxoplasmosis / Q000188:drug therapy*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy; D014125:Toxoplasmosis, Congenital / Q000517:prevention & control; D014295:Trimethoprim / Q000009:adverse effects / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole
Avenir thérapeutique du triméthoprime-sulfaméthoxazole dans la toxoplasmose.